Atogepant
Författaruppgift saknas
Tidskrift saknas · review PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för atogepant. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
32 träffarComparative Efficacy and Safety of Five Anti-calcitonin Gene-related Peptide Agents for Migraine Prevention: A Network Meta-analysis.
Sun W, Cheng H, Xia B, Liu X, Li Y, Wang X, Liu C.
Clin J Pain · network meta-analysis; journal article · DOI 10.1097/ajp.0000000000001136Update of Gepants in the Treatment of Chronic Migraine.
Cho S, Kim BK.
Curr Pain Headache Rep · review; journal article · DOI 10.1007/s11916-023-01167-6Effects of CYP3A4 inhibition/induction and OATP inhibition on the pharmacokinetics of atogepant in healthy adults.
Boinpally R, Chen W, McGeeney D, Trugman JM.
Pain Manag · journal article · DOI 10.2217/pmt-2023-0056Patient-reported migraine-specific quality of life, activity impairment and headache impact with once-daily atogepant for preventive treatment of migraine in a randomized, 52-week trial.
Lipton RB, Halker Singh RB, Mechtler L, McVige J, Ma J, Yu SY, Stokes J, Dabruzzo B, Gandhi P, Ashina M.
Cephalalgia · multicenter study; randomized controlled trial; journal article · DOI 10.1177/03331024231190296Blocking the CGRP Receptor: Differences across Human Vascular Beds.
de Vries T, Boucherie DM, van den Bogaerdt A, Danser AHJ, MaassenVanDenBrink A.
Pharmaceuticals (Basel) · research-article; journal article · DOI 10.3390/ph16081075Atogepant, the first oral preventive treatment for chronic migraine.
Haanes KA, Edvinsson L.
Lancet · comment; journal article · DOI 10.1016/s0140-6736(23)01462-9Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial.
Pozo-Rosich P, Ailani J, Ashina M, Goadsby PJ, Lipton RB, Reuter U, Guo H, Schwefel B, Lu K, Boinpally R, Miceli R, De Abreu Ferreira R, McCusker E, Yu SY, Severt L, Finnegan M, Trugman JM.
Lancet · clinical trial, phase iii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1016/s0140-6736(23)01049-8Evaluation of the pharmacokinetic interactions and safety of atogepant coadministered with esomeprazole.
Boinpally R, Butler M, Rojo J, Borbridge L, Wangsadipura V, Papinska A.
Pain Manag · clinical trial, phase i; journal article · DOI 10.2217/pmt-2023-0040Pharmacokinetics and Safety of Coadministered Atogepant and Topiramate in Healthy Participants: A Phase 1, Open-Label, Drug-Drug Interaction Study.
Boinpally R, McGeeney D, Borbridge L, Trugman J.
Clin Pharmacol Drug Dev · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1002/cpdd.1267The pharmacotherapeutic management of episodic and chronic migraine with gepants.
Tajti J, Szok D, Csáti A, Vécsei L.
Expert Opin Pharmacother · review; journal article · DOI 10.1080/14656566.2023.2201375Novel Oral CGRP Receptor Antagonist Atogepant in the Prevention of Migraine.
Chowdhury S, Dave T.
Discoveries (Craiova) · review-article; review; journal article · DOI 10.15190/d.2023.6Once-daily oral atogepant for the long-term preventive treatment of migraine: Findings from a multicenter, randomized, open-label, phase 3 trial.
Ashina M, Tepper SJ, Reuter U, Blumenfeld AM, Hutchinson S, Xia J, Miceli R, Severt L, Finnegan M, Trugman JM.
Headache · clinical trial, phase iii; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1111/head.14439Phase Ib, open-label, fixed-sequence, drug-drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraine.
Blumenfeld AM, Boinpally R, De Abreu Ferreira R, Trugman JM, Dabruzzo B, Ailani J, Lipton RB.
Headache · clinical trial, phase i; journal article · DOI 10.1111/head.14433Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial.
Klein BC, Miceli R, Severt L, McAllister P, Mechtler L, McVige J, Diamond M, Marmura MJ, Guo H, Finnegan M, Trugman JM.
Cephalalgia · multicenter study; journal article · DOI 10.1177/03331024221128250Gepants for Acute and Preventive Migraine Treatment: A Narrative Review.
Rissardo JP, Caprara ALF.
Brain Sci · review-article; review; journal article · DOI 10.3390/brainsci12121612Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial.
Lipton RB, Pozo-Rosich P, Blumenfeld AM, Li Y, Severt L, Stokes JT, Creutz L, Gandhi P, Dodick D.
Neurology · clinical trial, phase iii; research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1212/wnl.0000000000201568Atogepant for the prevention of episodic migraine in adults.
Switzer MP, Robinson JE, Joyner KR, Morgan KW.
SAGE Open Med · review-article; review; journal article · DOI 10.1177/20503121221128688Atogepant for migraine.
Bedrin K, Ailani J.
Drugs Today (Barc) · journal article · DOI 10.1358/dot.2022.58.8.3408815Atogepant for the Prevention of Episodic Migraine in Adults: A Systematic Review and Meta-Analysis of Efficacy and Safety.
Lattanzi S, Trinka E, Altamura C, Del Giovane C, Silvestrini M, Brigo F, Vernieri F.
Neurol Ther · research-article; journal article · DOI 10.1007/s40120-022-00370-8Rates of Response to Atogepant for Migraine Prophylaxis Among Adults: A Secondary Analysis of a Randomized Clinical Trial.
Lipton RB, Pozo-Rosich P, Blumenfeld AM, Dodick DW, McAllister P, Li Y, Lu K, Dabruzzo B, Miceli R, Severt L, Finnegan M, Trugman JM.
JAMA Netw Open · clinical trial, phase iii; research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.1001/jamanetworkopen.2022.15499Atogepant (Qulipta®) for migraine prevention.
Hay DL, Walker CS, Harris PWR.
Trends Pharmacol Sci · journal article · DOI 10.1016/j.tips.2022.03.013Role of Atogepant in the Treatment of Episodic Migraines: Clinical Perspectives and Considerations.
Cohen F, Yuan H.
Ther Clin Risk Manag · review-article; review; journal article · DOI 10.2147/tcrm.s348724Atogepant: an emerging treatment for migraine.
Rustichelli C, Avallone R, Ferrari A.
Expert Opin Pharmacother · journal article · DOI 10.1080/14656566.2022.2057221Small molecule CGRP receptor antagonists for the preventive treatment of migraine: A review.
Dos Santos JBR, da Silva MRR.
Eur J Pharmacol · review; journal article · DOI 10.1016/j.ejphar.2022.174902Atogepant - an orally-administered CGRP antagonist - attenuates activation of meningeal nociceptors by CSD.
Strassman AM, Melo-Carrillo A, Houle TT, Adams A, Brin MF, Burstein R.
Cephalalgia · research-article; journal article · DOI 10.1177/03331024221083544Atogepant for Migraine Prevention: A Systematic Review of Efficacy and Safety.
Singh A, Balasundaram MK.
Clin Drug Investig · systematic review; journal article · DOI 10.1007/s40261-022-01130-0The efficacy and safety of atogepant for the prophylactic treatment of migraine: evidence from randomized controlled trials.
Tao X, Yan Z, Meng J, Wang W, Dai Q, Zhou Q, Wang Z, Wang Z.
J Headache Pain · meta-analysis; research-article; journal article · DOI 10.1186/s10194-022-01391-2Atogepant: First Approval.
Deeks ED.
Drugs · review; journal article · DOI 10.1007/s40265-021-01644-5Atogepant.
Författaruppgift saknas
Am J Health Syst Pharm · journal article · DOI 10.1093/ajhp/zxab415